Patients
Nine patients diagnosed with relapsed non-M3 AML were treated with fludarabine and busulfan at the Blood and bone Marrow Transplantation center in Taleqani hospital (Tehran, Iran) between 2019 and 2022 were joined in this study. All patients signed informed consent before entering the study, and the advantage of their admission was explained verbally and in writing. All procedures in the present study were performed following the relevant guidelines and regulations of the Royan Institute and approved by the Institutional Review Board and Ethics Committee of the Royan Institute, Tehran, Iran (approval no. IR.ACECR.ROYAN.REC.1400.055). The main biological characteristics of the patients are in Table 1.